Bristol‑Myers Squibb posts Q3 beat, lifts 2026 revenue outlook but cuts FY EPS guidance

Bristol‑Myers Squibb reported third‑quarter 2026 revenue of $13.07 billion, up 7% year‑over‑year, and GAAP EPS of $1.05 (non‑GAAP $1.35). The company raised its full‑year 2026 revenue guidance to $49.75 billion‑$50.25 billion but lowered FY EPS guidance to $6.35‑$6.55 per share, citing $0.58‑$0.60 per‑share net impact from acquired IPRD charges and licensing income. Growth‑portfolio sales rose 12% to $7.7 billion, while legacy‑portfolio revenue grew 1%.

The higher revenue outlook expands the top‑line target for investors, while the reduced EPS guidance signals lower profitability for the year because of acquisition‑related charges. The guidance changes will affect valuation models that rely on revenue growth and EPS forecasts.

  • 1Third‑quarter revenues increased 7% to $13.1 billion.
  • 2GAAP EPS was $1.05 and non‑GAAP EPS was $1.35, each including a $(0.58) per‑share impact from acquired IPRD charges.
  • 3Full‑year 2026 revenue guidance was raised to a range of $49.75 billion‑$50.25 billion.
  • 4Full‑year non‑GAAP EPS guidance was updated to $6.35‑$6.55 per share, inclusive of a $(0.60) per‑share net impact from acquired IPRD charges.
  • 5Growth‑portfolio revenues were $7.7 billion, up 12% year‑over‑year.
  • 6Legacy‑portfolio revenues were $5.4 billion, up 1% year‑over‑year.

Sources